Prime Medicine, Inc. (PRME) Misses Q2 EPS by 6c

Prime Medicine, Inc. (NASDAQ: PRME) reported Q2 EPS of ($0.47), $0.06 worse than the analyst estimate of ($0.41).

For earnings history and earnings-related data on Prime Medicine, Inc. (PRME) click here.

You May Also Be Interested In

• BMO Capital Starts Prime Medicine (PRME) at Outperform
• Is the global equity rally broadening? UBS weighs in
• CoStar Group acquires Zonda for $800M, adding new home data